Bimiralisib

DB14846InvestigationalSmall molecule

Bimiralisib is under investigation in clinical trial NCT02723877 (PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)).

Chemical structure of Bimiralisib
Formula / weight
C17H20F3N7O2 · 411.389 g/mol (avg)
Code names
PQR309

Resolves to

Compound
UNII6Z3QHB00LBCAS1225037-39-7ChEMBLCHEMBL4084907
Structure
InChIKeyADGGYDAFIHSYFI-UHFFFAOYSA-NSMILESNC1=NC=C(C2=NC(=NC(=N2)N2CCOCC2)N2CCOCC2)C(=C1)C(F)(F)F
Targets
P42338PIK3CBP48736PIK3CGP42345MTOR

What you can answer from here — as of April 23, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
10Clinical trialsPhase, status and sponsor resolved per trial
Sign in
13+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Bimiralisib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In